Skip to main content
Fig. 3 | Critical Care

Fig. 3

From: Long-term ketamine infusion-induced cholestatic liver injury in COVID-19-associated acute respiratory distress syndrome

Fig. 3

Duration–effect and dose–effect relationship between ketamine (propofol) and total bilirubin levels. Time-varying, weighted cumulative exposure mixed-effects model assessing the multivariable adjusted duration of infusion–effect (a) and dose–effect (b) relationship of ketamine (propofol (c, d)) on rising bilirubin levels. Model estimates are depicted as solid lines and 95% confidence intervals as shaded areas

Back to article page